^
    Back
    Association details:
    Biomarker:AR F877L
    Cancer:Prostate Cancer
    Drug:Erleada (apalutamide) (Androgen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Med Chem
    Title:

    Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)

    Published date:
    01/20/2021
    Excerpt:
    The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide.
    DOI:
    10.1021/acs.jmedchem.0c01563
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

    Excerpt:
    The overall frequency of detected mutations at baseline (7.5%) and progression (7.3%) using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide.
    Trial ID:
    NCT01171898